Memoreel
Memoreel ®
Memoreel® is produced in Germany by Biologische Heilmittel Heel GmbH and marketed in Greece by A.S.K. Pharmaceutical as an OTC medicine.
Memoreel® is a multicomponent multitarget medication that is indicated for the adjuvant symptomatic treatment of cognitive disorders in elderly patients and to improve the quality of life, after the exclusion of dangerous conditions by the treating doctor (confirmed dementia, Parkinson’s disease, iatrogenic cognitive disorders or cognitive disorders secondary to a depression or due to metabolic dysfunctions).
Memoreel® is marketed in Germany under the name Vertigo-heel®.
Characteristics
Anamirta Cocculus
Sea sickness, calcification of brain vessels3, vertigo of various etiologies3, weakness of memory, dizziness4.
Conium Maculatum
Calcification of brain vessels3, weakened cerebral operation.4
Ambra Grisea
Calcification of brain vessels3, premature aging3, nervous fatigue.4
Petroleum Rectificatum
Vertigo3, confusion4, weakness of memory4.
Suitability
None known drug interactions.
No brain suppression.
Long treatment option.
Health professionals
- Memoreel Leaflet
- Citations
- Product Approved by EOF-Marketing Authorization Number: 61578/18 / 9-5-2019
-
C.Schnack, A.Hellrung, B.Seilheimer, Y. Burmeister, G.ST. Laurent III, M. Tackett, D. Schtokalo, C.A.F. von Arnim, K. Roeska. A multicomponent medication (HE-300) targets the mechanisms related to Alzheimer disease: in-vitro & in-vivo assessment. November 15, 2011
T. Heilkkinen, B. Seilheimer, J. Puoliväli, A. Nurmi, R. Pussinen, D. Lescheid, Y. Burmeister, K. Roeska. Beneficial effect of a multicomponent medication (HE-300) on scopolamine-induced social transmission of food preference in mice and passive avoidance deficits in rats. November 16, 2011
E. Andriambeloson, S. Wagner, Y. Burmeister, K. Roeska, B. Seilheimer. A multicomponent medication enhances cognitive function in vivo. November 16, 2011
Dimpfel, W. , Seilheimer, B. and Schombert, L. (2019) In Vitro Hippocampal Electrophysiology and in Vivo Quantitative EEG Revealed Robust Neurophysiological Effects of the Antivertigo-Agent Vertigoheel® in a Rat Study. Neuroscience and Medicine, 10, 407-425.
- Παραδοσιακή ομοιοπαθητική χρήση σύμφωνα με τη Μονογραφία της Γερμανικής Επιτροπής D.
- Χρήση σύμφωνα με την ομοιοπαθητική βιβλιογραφία.
Report side effects
- How can I report side effects?
Healthcare professionals are asked to report any suspected adverse reactions via the National Organization of Medicines. If you are a patient and you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the package leaflet. You can report adverse reactions with the following options :
1) Electronic submission through EOF’s website http://www.eof.gr/web/guest/yellowgeneral
2) Dispatching the Yellow card in hard copy via mail to EOF to the Department of Adverse Reactions (Mesogeion 284, Cholargos 15562)
3) Communication with the Department of Adverse Reactions via telephone : 213.20.40.380-337
4) Submission of the yellow card via fax at 210.6549.585
